Sirion Biotech announces a collaboration and license agreement with Sanofi to develop gene therapy treatments with improved adeno-associated virus capsids
Sirion Biotech, a world leader in viral vector-based gene delivery technologies for gene and cell therapy, announced today that it signed a collaboration and license agreement with Sanofi, a global biopharmaceutical company, to develop improved tissue-selective adeno-associated virus (AAV) vectors to realize effective gene therapy treatments. The aim of the collaboration is to develop new and modified AAV capsids with improved specificity and higher gene delivery efficiency.
“AAV vectors with improved efficacy can enable quickly entering into clinical trials with efficient, safe low doses and scalable therapeutic candidates and can expand the impact of gene therapies,” states Dr. Christian Thirion, CEO and Co-Founder of Sirion.
Maiwald Patentanwalts- und Rechtsanwaltsgesellschaft mbH, in particular Dr Andreas Ledl and Dr Marco Stief, acted as legal advisors to Sirion Biotech GmbH.
The full text version of the press release can be found here.
